This technology is a mechanosensitive induction method designed to enhance induced regulatory T cell (iTreg) production for adoptive immunotherapy by modulating substrate stiffness to improve cell stability and function.
Current treatments for autoimmune diseases rely heavily on broad-spectrum immunosuppressants, which can impair the immune system's overall function and increase the risk of infections. Although adoptive T cell therapies provide a more targeted approach, traditional methods often produce induced regulatory T cells (iTregs) with limited stability and functional durability. This lack of consistency in T cell performance reduces the potential effectiveness of adoptive immunotherapy as a sustainable solution for autoimmune disease management. There is a clear need for therapies capable of generating stable, high-functioning iTregs to offer a precise, long-lasting alternative to current treatments.
This technology is a mechanosensitive method that enhances regulatory T cell (iTreg) induction by modulating substrate stiffness to activate key pathways involved in T cell differentiation and stabilization. By adjusting the substrate’s rigidity, this approach produces iTregs with improved stability and functionality, enabling them to sustain immune modulation effectively. This mechanosensitive approach promotes more consistent T cell regulation by influencing transcriptional activity, thereby addressing the limitations of conventional T cell therapies and improving strategies for treating autoimmune diseases.
This technology has been validated in vitro.
Patent Pending (WO/2025/184248)
IR CU23392
Licensing Contact: Dovina Qu
